Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?

Merck (MRK) is acquiring Verona Pharma (VRNA) for approximately $10 billion, primarily to integrate Ohtuvayre, an FDA-approved COPD drug, into its portfolio. This strategic move aims to diversify Merck's revenue streams and bolster its pipeline as its blockbuster oncology drug, Keytruda, approaches patent expiry in 2028 and faces increasing competition. Despite current headwinds like underperforming stock and declining Gardasil sales in China, the Verona deal, alongside successful launches of new products such as Capvaxive and Winrevair, is crucial for Merck's long-term growth and its ability to mitigate potential revenue gaps.

Analysis

Merck is executing a critical strategic pivot with the $10 billion acquisition of Verona Pharma, aiming to mitigate its heavy reliance on Keytruda, which constitutes approximately 50% of its pharmaceutical sales and faces patent expiration in 2028. This move adds Ohtuvayre, a differentiated COPD therapy, to its portfolio, which has already demonstrated commercial traction with $71.3 million in Q1 sales, a 95% sequential increase. The acquisition is part of a broader strategy to de-risk the business, which includes a phase III pipeline that has nearly tripled since 2021 and strong initial launches for new drugs Capvaxive and Winrevair. However, Merck faces significant headwinds, including the stock's 14.0% year-to-date decline, falling EPS estimates for 2025-2026, and specific operational challenges. These include a halt in shipments of its second-largest product, Gardasil, to China due to weak demand and emerging competitive threats to Keytruda, notably from Summit Therapeutics' ivonescimab which outperformed it in a recent study. Despite these pressures, the company's valuation appears attractive, with a forward P/E ratio of 8.99, well below both the industry average of 15.16 and its own five-year mean of 12.82.

Key Decisions for Investors

• Given the stock's recent underperformance and a forward P/E ratio significantly below industry and historical averages, long-term value investors may consider the current price an attractive entry point, betting on the success of the company's diversification strategy.
• Investors should closely monitor the execution of Merck's pipeline, particularly the sales trajectory of newly launched products Ohtuvayre, Capvaxive, and Winrevair, as their success is crucial to offsetting the eventual decline of Keytruda.
• Key risk factors to track are the competitive landscape for Keytruda, especially further data from Summit Therapeutics, and any resolution or continued weakness in Gardasil sales in China, which could materially impact revenue guidance.
• A key upcoming catalyst is the FDA's decision on the subcutaneous formulation of Keytruda, expected in September, which could extend the drug's revenue-generating life and impact medium-term sentiment.